Ticker

UTMD's Q4 earnings fall year over year due to weak OEM sales and lower international Filshie sales, but strong U.S. Filshie growth and steady margins help offset broader revenue pressure.

SALT LAKE CITY, UT / ACCESS Newswire / February 4, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty-one cents ($.31) per share of common stock payable on April 3, 2026 to stockholders of record at the close of business on March 17, 2026. This is a 1.6% increase over the dividend declared in the same quarter of the prior year.

SALT LAKE CITY, UT / ACCESS Newswire / January 29, 2026 / With some unexpected circumstances in 2025, Utah Medical Products, Inc (UTMD) did not achieve its beginning of year financial projections. Nevertheless the Company retained excellent profit margins, and increased its year-ending cash balances to $85.8 million despite paying $4.0 million in dividends to stockholders and repurchasing 4.5% (since the end of…

Shares of Utah Medical Products, Inc. (NASDAQ: UTMD - Get Free Report) crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $56.49 and traded as high as $58.76. Utah Medical Products shares last traded at $57.60, with a volume of 19,913 shares changing hands. Analyst Ratings

Terumo (OTCMKTS:TRUMY - Get Free Report) and Utah Medical Products (NASDAQ: UTMD - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings. Insider and Institutional Ownership 69.6% of Utah Medical